- Home
- AGIO vs CIM Comparison
AGIO vs CIM Comparison
Compare AGIO & CIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- CIM
- Stock Information
- Founded
- AGIO 2007
- CIM 2007
- Country
- AGIO United States
- CIM United States
- Employees
- AGIO N/A
- CIM N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- CIM Real Estate Investment Trusts
- Sector
- AGIO Health Care
- CIM Real Estate
- Exchange
- AGIO Nasdaq
- CIM Nasdaq
- Market Cap
- AGIO 1.4B
- CIM 1.1B
- IPO Year
- AGIO 2013
- CIM 2007
- Fundamental
- Price
- AGIO $39.23
- CIM $13.99
- Analyst Decision
- AGIO Buy
- CIM Buy
- Analyst Count
- AGIO 6
- CIM 3
- Target Price
- AGIO $58.60
- CIM $15.50
- AVG Volume (30 Days)
- AGIO 615.0K
- CIM 549.5K
- Earning Date
- AGIO 07-31-2025
- CIM 08-06-2025
- Dividend Yield
- AGIO N/A
- CIM 10.59%
- EPS Growth
- AGIO N/A
- CIM N/A
- EPS
- AGIO 11.45
- CIM 1.52
- Revenue
- AGIO $37,035,000.00
- CIM $326,755,000.00
- Revenue This Year
- AGIO $22.30
- CIM $18.94
- Revenue Next Year
- AGIO $219.19
- CIM $3.05
- P/E Ratio
- AGIO $3.39
- CIM $9.20
- Revenue Growth
- AGIO 25.96
- CIM 11.90
- 52 Week Low
- AGIO $23.42
- CIM $9.85
- 52 Week High
- AGIO $62.58
- CIM $16.89
- Technical
- Relative Strength Index (RSI)
- AGIO 70.51
- CIM 53.36
- Support Level
- AGIO $34.60
- CIM $14.09
- Resistance Level
- AGIO $40.06
- CIM $14.43
- Average True Range (ATR)
- AGIO 1.45
- CIM 0.23
- MACD
- AGIO 0.43
- CIM -0.04
- Stochastic Oscillator
- AGIO 88.98
- CIM 45.00
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.